Cargando…

Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia

Essential thrombocythemia (ET) is a BCL-ABL1-negative myeloproliferative neoplasm. We have reported that increased activated B cells can facilitate platelet production mediated by cytokines regardless JAK2 mutational status in ET. Recently, calreticulin (CALR) mutations were discovered in ~30% JAK2/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Ken-Hong, Chen, Caleb Gon-Shen, Chang, Yu-Cheng, Chiang, Yi-Hao, Kao, Chen-Wei, Wang, Wei-Ting, Chang, Chiao-Yi, Huang, Ling, Lin, Ching-Sung, Cheng, Chun-Chia, Cheng, Hung-I, Su, Nai-Wen, Lin, Johnson, Chang, Yi-Fang, Chang, Ming-Chih, Hsieh, Ruey-Kuen, Lin, Huan-Chau, Kuo, Yuan-Yeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464803/ https://www.ncbi.nlm.nih.gov/pubmed/28415571 http://dx.doi.org/10.18632/oncotarget.16381

Ejemplares similares

Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis
por: Lim, K-H, et al.
Publicado: (2015)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia
por: Kang, Min-Gu, et al.
Publicado: (2016)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
por: Kubuki, Yoko, et al.
Publicado: (2017)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
por: Langabeer, Stephen E., et al.
Publicado: (2016)

Splenic mass in a case of CALR‐mutated essential thrombocythemia
por: Imashuku, Shinsaku, et al.
Publicado: (2018)

Retinal neovascularization in the setting of CALR-mutation positive essential thrombocythemia
por: Heydinger, Stanton P, et al.
Publicado: (2023)

Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population
por: Chiang, Yi-Hao, et al.
Publicado: (2017)

Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review
por: Chen, Rong, et al.
Publicado: (2022)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL
por: Wang, Yan, et al.
Publicado: (2023)

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

Oral squamous cell carcinoma with essential thrombocythemia and positive JAK2 (V617F) mutation
por: Rahman, Kurnia H., et al.
Publicado: (2021)

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
por: Abdelghani, Maroua, et al.
Publicado: (2022)

Case report: Double L611S/V617L JAK2 mutation in a patient with polycythemia vera originally diagnosed with essential thrombocythemia
por: Li, Xiao-qing, et al.
Publicado: (2022)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter
por: Trifa, Adrian P., et al.
Publicado: (2014)

Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia
por: Blouet, Anaïse, et al.
Publicado: (2018)

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
por: Zulkeflee, Razan Hayati, et al.
Publicado: (2021)

Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms
por: Wiriyaukaradecha, Kriangpol, et al.
Publicado: (2022)

A case of ischemic stroke with hemorrhagic transformation associated with essential thrombocythemia and JAK-2 V617F mutation
por: Yan, Ran, et al.
Publicado: (2022)

PB2250: THE IMPACT OF JAK2V617F MUTATION POSITIVITY IN ESSENTIAL THROMBOCYTHEMIA:ABOUT 74 CASES.
por: Cheffai, Arij, et al.
Publicado: (2023)

HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report
por: Krzysztof, Lewandowski, et al.
Publicado: (2023)

Incidence, Clinical Features, and Prognostic Impact of CALR Exon 9 Mutations in Essential Thrombocythemia and Primary Myelofibrosis: An Experience of a Single Tertiary Hospital in Korea
por: Park, Sang Hyuk, et al.
Publicado: (2015)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles
por: Zini, Roberta, et al.
Publicado: (2017)

Simultaneous presentation of JAK2 V617F mutation-related essential thrombocythemia and B-cell chronic lymphocytic leukemia
por: D'Angelo, Guido, et al.
Publicado: (2014)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
por: Mejía-Ochoa, Mónica, et al.
Publicado: (2019)

Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2(V617F)-positive Essential Thrombocythemia
por: Chen, Wei-Bi, et al.
Publicado: (2018)

Low-level somatic JAK2 V617F mutation in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR
por: Ji, Young Sok, et al.
Publicado: (2022)

Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations
por: Makarik, Tatiana V., et al.
Publicado: (2021)

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?
por: Morsia, E., et al.
Publicado: (2022)

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
por: Cascavilla, Nicola, et al.
Publicado: (2015)

Chronic urticaria reveals JAK2V617F positive essential thrombocythemia
por: Albanesi, Marcello, et al.
Publicado: (2021)

Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish
por: Lim, K-H, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2r5a8fm3g8kopgoc1ep78sl5op